In the ACR Convergence 2021 session on Updates in OA, presenters discuss the debate over OA phenotypes vs. endotypes, as well as note that research conducted over the past 20 years yields a better understanding of the pathogenesis of OA.
Pegloticase Proves Promising for Gout in Patients Who Have Undergone Kidney Transplant
Patients who have undergone a kidney transplant and have high levels of serum uric acid symptomatic gout may benefit from treatment with pegloticase, according to a recent study.
Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More
ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…
Update on Extrapulmonary Sarcoidosis
Neurosarcoidosis & sarcoid dermatopathology are discussed.
Good Flow: 2021 Updates in Vasculitis
During the ACR Convergence 2021 annual Review Course, Peter Merkel, MD, MPH, provided recent updates on vasculitis.
Bethany Marston, MD, Assumes Chair of Committee on Rheumatology Training & Workforce Issues
Noting that the pandemic has shifted what and how rheumatology trainees learn, Dr. Marston hopes the Committee on Rheumatology Training & Workforce Issues can work to understand current workforce needs and explore new educational opportunities.
ACR Town Hall Offers Research, Tips on Physician Burnout
Physician burnout takes a toll not just on providers, but on their patients and practices as well. Speakers at a recent ACR town hall provided research-based tips to help address the root causes of burnout.
ACR Works for Modifications to Build Back Better Act
The ACR has long supported efforts to reduce drug prices through many of the provisions included in the House-passed version of the Build Back Better Act. However, the current wording of one provision puts patient access to Medicare Part B treatments at risk.
Guselkumab Boosts Response in Resistant Psoriatic Arthritis
NEW YORK (Reuters Health)—In patients with psoriatic arthritis (PsA) who are resistant to tumor necrosis factor inhibitors (TNFi), guselkumab was more effective than placebo in a phase 3b trial. “Guselkumab is a relatively new treatment and is the first drug in its class (IL-23 inhibitor) to gain approval for PsA,” Dr. Laura Coates of the…
Tofacitinib Yields Rapid & Sustained Improvement in JIA
NEW YORK (Reuters Health)—Tofacitinib significantly reduces the number of flares in children with polyarticular course juvenile idiopathic arthritis (JIA), according to the first phase-3 clinical trial to assess the efficacy of a Janus kinase (JAK) inhibitor in JIA. JIA is a heterogeneous group of chronic conditions with no known cause that develop before age 16…
- « Previous Page
- 1
- …
- 103
- 104
- 105
- 106
- 107
- …
- 800
- Next Page »